Compare Gilead Sciences, Inc. (GILD) vs Macy's Inc (M) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Macy's Inc — how do they compare? Gilead Sciences, Inc. trades at $135.54 (market cap $163.51B), while Macy's Inc trades at $24.1 (market cap $6.25B). The key difference: Gilead Sciences, Inc. is far larger — about 26.2× Macy's Inc's market cap, and Macy's Inc pays the higher dividend (3.22%). Which is the better fit depends on your goals.
| GILD | M | |
|---|---|---|
Market Cap | $163.51B | $6.25B |
Sector | Health | Consumer Cyclical |
52-Week High | $155.80 | $25.96 |
52-Week Low | $108.22 | $11.90 |
Enterprise Value | $178.05B | $10.06B |
Dividend Yield | 2.49% | 3.22% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
Macy's (M) trades at $24.04, up 3.55% today, with a bullish technical signal and positive earnings momentum after beating estimates in three consecutive quarters. The stock shows attractive valuation metrics with a P/E of 9.82 and P/S of 0.29, while recent news highlights strategic initiatives including AI integration and leadership appointments. Cash flow trends improved in 2025 with net cash flow of $273 million, though revenue declined slightly to $23.01 billion.
Outlook remains cautiously optimistic with a consensus price target of $24.83 offering modest upside. Key opportunities include operational efficiency gains and luxury segment growth, while risks involve competitive retail pressures and macroeconomic sensitivity. Institutional interest is growing with Berkshire Hathaway's recent 3 million share purchase (Barron's, June 22, 2026).
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Macy's Inc
Founded in 1858 and based in New York City, Macy's operates 570 stores under the Macy's nameplate, 58 stores under the Bloomingdale's nameplate, and 160 freestanding Bluemercury specialty beauty stores (as of the end of fiscal-year 2021). Macy's also operates e-commerce sites and licenses two Bloomingdale's stores in the United Arab Emirates and Kuwait. Women's apparel, accessories, shoes, cosmetics, and fragrances comprised 59% of Macy's 2021 sales.
Read more on M →
